Flamel kept at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam maintained Flamel Technologies SA at neutral ahead of release of the company's quarterly results. The analyst estimates total revenues of $5.5 million, total expenses of $17.3 million and a net loss of $11.4 million, or $0.48 per share. During the conference call, Merrill will look for updates on how Flamel plans to commercialize Coreg. Shares of the Venissieux, France-based biopharmaceutical company were up 26 cents, or 1.46%, at $18.11 on volume of 57,128 shares versus the three-month running average of 106,166 shares. (Nasdaq: FLML)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.